login
  Password reminder
Spinal News
Contact the editor Visit Spinal News Twitter feed Visit Spinal News Facebook page
 

Alphatec comments on FDA’s letter regarding PureGen product for spinal fusion procedures


Thursday, 28 Jul 2011 12:26

Alphatec commented on the Food and Drug Administration’s (FDA) untitled letter that was sent to Parcell Laboratories on 23 June 2011 regarding Alphatec Spine’s PureGen osteoprogenitor cell allograft product for spinal fusion procedures for cervical and lumbar spine.


The FDA’s letter raised questions in connection with Parcell Laboratories’s position that the PureGen product is within the classification of human cell, tissue, and cellular or tissue-based products regulated solely under FDA’s regulation. 


Parcell Laboratories has responded to the FDA’s letter on 21 July 2011 with more complete information of the function of PureGen and how the product meets all of the criteria for being marketed under FDA’s regulation.   


Dirk Kuyper, Alphatec Spine’s president and CEO, stated, “Both Alphatec Spine and Parcell Laboratories are fully committed to work closely and collaboratively with the FDA to address the questions related to the PureGen product. We look forward to discussing the PureGen product with the FDA and sharing our clinical outcomes to date.”

 

About PureGen osteoprogenitor cell allograft

 

PureGen is a highly concentrated, pure population of adult stem cells that originates in bone marrow and is collected from live, healthy donors for optimal cell functionality. Unlike stem cell products that are currently commercially available, which have an unknown population of mesenchymal stem cells (MSCs) and are harvested from cadaveric donor tissue, PureGen delivers a similar potency of a pure adult MSCs without the need for cultural expansion.

 

The PureGen osteoprogenitor cell allograft was launched in October 2010 and has been successfully implanted in over 500 patients with no reported adverse events, complications or complaints. The product is used primarily in spinal fusion procedures for both cervical and lumbar spine. There are three controlled prospective studies currently underway to further establish the performance of the product by both academic and community-based spine surgeons.


To read FDA’s untitled letter please click here




Add New Comment

Most popular


Epidural glucocorticoid injections provide little or no benefit for spinal stenosis
Friday, 11 Jul 2014
A new study indicates that epidural injections of glucocorticoids and lidocaine provide little or no benefit compared with epidural injections of lidocaine alone for patients with lumbar spinal ... Epidural glucocorticoid injections provide little or no benefit for spinal stenosis

Trial shows significant pain relief for spine cancer patients following targeted radiofrequency ablation treatment
Wednesday, 23 Jul 2014
The study followed patients at five leading academic centres and found a significant decrease (p <0.01) in pain scores after targeted radiofrequency ablation (t-RFA) with the Star (DFINE) tumour ... Trial shows significant pain relief for spine cancer patients following targeted radiofrequency ablation treatment

CE mark for FLXfit 3D expandable interbody cage
Tuesday, 01 Jul 2014
Expanding Orthopedics has announced that the FLXfit, its novel expandable and articulated TLIF cage with lordotic correction, has received CE mark approval and is now cleared for commercialisation in ... CE mark for FLXfit 3D expandable interbody cage

Features


The ASIA impairment scale for spinal injuries may show worsening despite neurological improvement
Thursday, 31 Jul 2014
Ibrahim Gündoğdu and colleagues report in Spinal Cord that the American Spinal Injury Association (ASIA) impairment scale is limited because it could show worsening despite a patient with a spinal ... The ASIA impairment scale for spinal injuries may show worsening despite neurological improvement

Can cognitive behavioural therapy help spinal surgery patients return to work and daily life?
Friday, 11 Jul 2014
Nanna Rolving and colleagues have launched a study to investigate the clinical effectiveness and cost-effectiveness of using a multidisciplinary cognitive behavioural intervention to help patients ... Can cognitive behavioural therapy help spinal surgery patients return to work and daily life?

Profiles


Lori Karol
Wednesday, 13 Aug 2014
Lori Karol, Texas Scottish Rite Hospital, Dallas, USA, talks to Spinal News International about the ... Lori Karol

Luiz Pimenta
Thursday, 12 Jun 2014
Luiz Pimenta, immediate past president of the International Society for the Advancement of Spinal S... Luiz Pimenta

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions